Page 35 - Read Online

Brault et al. J Transl Genet Genom. 2025;9:1-10 https://dx.doi.org/10.20517/jtgg.2024.83 Page 9

51. Goncalves RLS, Schlame M, Bartelt A, Brand MD, Hotamışlıgil GS. Cardiolipin deficiency in Barth syndrome is not associated with
increased superoxide/H O production in heart and skeletal muscle mitochondria. FEBS Lett. 2021;595:415-32. DOI PubMed PMC
2 2
52. Zhu S, Chen Z, Zhu M, et al. Cardiolipin remodeling defects impair mitochondrial architecture and function in a murine model of
Barth syndrome cardiomyopathy. Circ Heart Fail. 2021;14:e008289. DOI PubMed PMC
53. Chowdhury A, Boshnakovska A, Aich A, et al. Metabolic switch from fatty acid oxidation to glycolysis in knock-in mouse model of
Barth syndrome. EMBO Mol Med. 2023;15:e17399. DOI PubMed PMC
54. Pacak CA, Suzuki-Hatano S, Khadir F, et al. One episode of low intensity aerobic exercise prior to systemic AAV9 administration
augments transgene delivery to the heart and skeletal muscle. J Transl Med. 2023;21:748. DOI PubMed PMC
55. Liang Z, Ralph-Epps T, Schmidtke MW, et al. Upregulation of the AMPK-FOXO1-PDK4 pathway is a primary mechanism of
pyruvate dehydrogenase activity reduction in tafazzin-deficient cells. Sci Rep. 2024;14:11497. DOI PubMed PMC
56. Ferrara PJ, Lang MJ, Johnson JM, et al. Weight loss increases skeletal muscle mitochondrial energy efficiency in obese mice. Life
Metab. 2023;2:load014. DOI PubMed PMC
57. Dudek J, Cheng IF, Chowdhury A, et al. Cardiac-specific succinate dehydrogenase deficiency in Barth syndrome. EMBO Mol Med.
2016;8:139-54. DOI PubMed PMC
58. Soustek MS, Baligand C, Falk DJ, Walter GA, Lewin AS, Byrne BJ. Endurance training ameliorates complex 3 deficiency in a mouse
model of Barth syndrome. J Inherit Metab Dis. 2015;38:915-22. DOI
2+
59. Liu X, Wang S, Guo X, et al. Increased reactive oxygen species-mediated Ca /calmodulin-dependent protein kinase II activation
contributes to calcium handling abnormalities and impaired contraction in Barth syndrome. Circulation. 2021;143:1894-911. DOI
PubMed PMC
60. He Q, Harris N, Ren J, Han X. Mitochondria-targeted antioxidant prevents cardiac dysfunction induced by tafazzin gene knockdown in
cardiac myocytes. Oxid Med Cell Longev. 2014;2014:654198. DOI PubMed PMC
61. Greenwell AA, Tabatabaei Dakhili SA, Ussher JR. Myocardial disturbances of intermediary metabolism in Barth syndrome. Front
Cardiovasc Med. 2022;9:981972. DOI PubMed PMC
62. Milon L, Meyer P, Chiadmi M, et al. The human nm23-H4 gene product is a mitochondrial nucleoside diphosphate kinase. J Biol
Chem. 2000;275:14264-72. DOI
63. Tokarska-Schlattner M, Boissan M, Munier A, et al. The nucleoside diphosphate kinase D (NM23-H4) binds the inner mitochondrial
membrane with high affinity to cardiolipin and couples nucleotide transfer with respiration. J Biol Chem. 2008;283:26198-207. DOI
PubMed PMC
64. Meyer RA, Sweeney HL, Kushmerick MJ. A simple analysis of the “phosphocreatine shuttle”. Am J Physiol. 1984;246:C365-77. DOI
PubMed
65. Schlattner U, Gehring F, Vernoux N, et al. C-terminal lysines determine phospholipid interaction of sarcomeric mitochondrial creatine
kinase. J Biol Chem. 2004;279:24334-42. DOI
66. Schlattner U, Tokarska-Schlattner M, Ramirez S, et al. Dual function of mitochondrial Nm23-H4 protein in phosphotransfer and
intermembrane lipid transfer: a cardiolipin-dependent switch. J Biol Chem. 2013;288:111-21. DOI PubMed PMC
67. Schlattner U, Tokarska-Schlattner M, Rousseau D, et al. Mitochondrial cardiolipin/phospholipid trafficking: the role of membrane
contact site complexes and lipid transfer proteins. Chem Phys Lipids. 2014;179:32-41. DOI
68. Gonzalvez F, D’Aurelio M, Boutant M, et al. Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis
inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation. Biochim Biophys Acta. 2013;1832:1194-
206. DOI
69. Aryal B, Rao VA. Deficiency in cardiolipin reduces doxorubicin-induced oxidative stress and mitochondrial damage in human B-
lymphocytes. PLoS One. 2016;11:e0158376. DOI PubMed PMC
70. Wang G, McCain ML, Yang L, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem
cell and heart-on-chip technologies. Nat Med. 2014;20:616-23. DOI
71. He Q. Tafazzin knockdown causes hypertrophy of neonatal ventricular myocytes. Am J Physiol Heart Circ Physiol. 2010;299:H210-6.
DOI PubMed
72. He Q, Wang M, Harris N, Han X. Tafazzin knockdown interrupts cell cycle progression in cultured neonatal ventricular fibroblasts.
Am J Physiol Heart Circ Physiol. 2013;305:H1332-43. DOI
73. Suzuki-Hatano S, Sriramvenugopal M, Ramanathan M, et al. Increased mtDNA abundance and improved function in human Barth
syndrome patient fibroblasts following AAV-TAZ gene delivery. Int J Mol Sci. 2019;20:3416. DOI PubMed PMC
74. Gürtler S, Wolke C, Otto O, et al. Tafazzin-dependent cardiolipin composition in C6 glioma cells correlates with changes in
mitochondrial and cellular functions, and cellular proliferation. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864:452-65. DOI
75. Rua AJ, Mitchell W, Claypool SM, Alder NN, Alexandrescu AT. Perturbations in mitochondrial metabolism associated with defective
cardiolipin biosynthesis: an in-organello real-time NMR study. J Biol Chem. 2024;300:107746. DOI PubMed PMC
76. Huang Y, Powers C, Madala SK, et al. Cardiac metabolic pathways affected in the mouse model of Barth syndrome. PLoS One.
2015;10:e0128561. DOI PubMed PMC
77. Wang S, Li Y, Xu Y, et al. AAV gene therapy prevents and reverses heart failure in a murine knockout model of Barth syndrome. Circ
Res. 2020;126:1024-39. DOI PubMed PMC
78. Snider PL, Sierra Potchanant EA, Matias C, Edwards DM, Brault JJ, Conway SJ. The loss of tafazzin Transacetylase activity is
sufficient to drive testicular infertility. J Dev Biol. 2024;12:32. DOI PubMed PMC